logo
Plus   Neg
Share
Email

PDL BioPharma Inc. (PDLI) Is Up Sharply Following Q4 Report

PDL BioPharma Inc. (PDLI) reported fourth quarter GAAP EPS of $0.15 after the bell Thursday, compared to the loss of $0.06 in the prior year. Total revenues came in at $68.0 million.

PDL BioPharma has gapped open sharply higher Friday morning and is now up 0.41 at $3.06. The stock has jumped to a 4-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT